Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents
- PMID: 18533766
Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents
Abstract
When taking antipsychotic medications, children and adolescents seem to have a higher risk than adults for experiencing adverse events such as extrapyramidal symptoms, prolactin elevation, sedation, weight gain, and metabolic effects. Side effects may be predicted by the pharmacologic binding profiles of antipsychotics to certain neuroreceptors. Data from 7 recently completed randomized placebo-controlled trials in adolescent schizophrenia and pediatric bipolar disorder that included a total of 1480 patients extend prior results and provide numbers-needed-to-harm as a clinically useful measure of risk. Results from these pediatric studies indicate that adverse effect profiles differ among commonly used antipsychotics. However, more detailed data are needed, as information is lacking regarding carryover or withdrawal effects from prior medications and regarding the masking of effects by adjunctive treatments used to treat agitation, insomnia, or extrapyramidal symptoms and akathisia in these studies. Moreover, randomized head-to-head trials and large-scale studies that investigate predictors of adverse effects as well as the safety and efficacy of interventions aimed at preventing and reversing negative effects of antipsychotics with relevant impact on psychological, psychiatric, and physical functioning are lacking. When choosing an antipsychotic treatment, patients and their families should be included in a careful risk-benefit assessment. Consideration of adverse effects, as well as dietary and lifestyle counseling, should be part of any antipsychotic treatment initiation and continuation. Routine, proactive monitoring of side effects is essential to optimize patient outcomes. In all treatment decisions, the benefits of improving often severe and debilitating manic, psychotic, and aggressive symptomatology must be balanced against the varying risks of adverse effects associated with specific antipsychotic agents in child and adolescent patients.
Similar articles
-
Addressing adverse effects of antipsychotic treatment in young patients with schizophrenia.J Clin Psychiatry. 2011 Jan;72(1):e01. doi: 10.4088/JCP.9101tx6c. J Clin Psychiatry. 2011. PMID: 21272508
-
Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients.Int Rev Psychiatry. 2008 Apr;20(2):195-201. doi: 10.1080/09540260801889179. Int Rev Psychiatry. 2008. PMID: 18386212 Review.
-
Safety and tolerability of antipsychotic treatment in young patients with schizophrenia.J Clin Psychiatry. 2011 Aug;72(8):e26. doi: 10.4088/JCP.9101tx5c. J Clin Psychiatry. 2011. PMID: 21899814
-
Use of antipsychotics in children and adolescents.J Clin Psychiatry. 2005;66 Suppl 7:29-40. J Clin Psychiatry. 2005. PMID: 16124839 Review.
-
Some adverse effects of antipsychotics: prevention and treatment.J Clin Psychiatry. 1999;60 Suppl 12:18-21. J Clin Psychiatry. 1999. PMID: 10372605 Review.
Cited by
-
Is Adjunct Aripiprazole Effective in Treating Hyperprolactinemia Induced by Psychotropic Medication? A Narrative Review.CNS Drugs. 2021 May;35(5):507-526. doi: 10.1007/s40263-021-00812-1. Epub 2021 Apr 20. CNS Drugs. 2021. PMID: 33880739 Review.
-
Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial.BMC Psychiatry. 2014 Jul 11;14:199. doi: 10.1186/1471-244X-14-199. BMC Psychiatry. 2014. PMID: 25015535 Free PMC article. Clinical Trial.
-
Attenuated psychotic and basic symptom characteristics in adolescents with ultra-high risk criteria for psychosis, other non-psychotic psychiatric disorders and early-onset psychosis.Eur Child Adolesc Psychiatry. 2016 Oct;25(10):1091-102. doi: 10.1007/s00787-016-0832-7. Epub 2016 Feb 26. Eur Child Adolesc Psychiatry. 2016. PMID: 26921232
-
Guideline Adherence of Monitoring Antipsychotic Use for Nonpsychotic Indications in Children and Adolescents: A Patient Record Review.J Clin Psychopharmacol. 2021 Jan/Feb 01;41(1):13-18. doi: 10.1097/JCP.0000000000001322. J Clin Psychopharmacol. 2021. PMID: 33347017 Free PMC article.
-
Prescribing patterns for treatment of pediatric bipolar disorder in a specialty clinic.J Child Adolesc Psychopharmacol. 2009 Oct;19(5):529-38. doi: 10.1089/cap.2008.0142. J Child Adolesc Psychopharmacol. 2009. PMID: 19877977 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical